

International Partnership for Microbicides



'Access' to Microbicides: Key Challenges and Possible Scenarios

Microbicide Access Forum, Nairobi
Saul Walker

July 2007



Access Objectives

- Maximise microbicide health impact over time for women in developing countries
 - Establish evidence base to support initial introduction and later scale up
 - Situate microbicides as part of comprehensive response to HIV
 - Address components of access: availability, acceptability, accessibility and affordability
 - Mobilise partnerships: country, finance, manufacture, distribution and programme



Microbicide Access Challenges

- Timing and product profile unclear
- First-in-class product
 - No historical demand data
 - No simple analogue
 - Product use understood from trials
- Unit costs vary by formulation
- Partial effectiveness
 - Perfect use and 'normal' use




Microbicide Access Challenges

- Association with HIV
 - FC experience
- Gender roles
 - ‘Empowerment’ a key issued but ...
 - how to include male partners?
- Demonstrating impact
 - Attribution as part of method mix
 - Dynamic HIV-prevention field
 - Time taken to show population effects



Critical Path to Access





Critical Path to Access


- Sequence activities
- Need for partnerships
- *Timely* mobilisation
- Evidence for different decision makers
- Scenario planning
 - When, where and what microbicide introduced
- Manage expectations




Critical Path to Access

Next

Early



Current Microbicide Trial Results





Early-Generation Microbicides

- Data late 2007 - 2009
- No, low or partial efficacy
- Gel plus applicator-based products
- Likely prescription only
- Some contraceptive, some not



Early-Generation Microbicides

- Use needed per sex act
- Manufacturing options available
- Cost \approx \$0.5 but scale efficiencies expected



Next-Generation Microbicides

- First efficacy now and others in safety
- Various formulations
 - Gels, rings, tablets, films ...
- Prescription only (at least initially)
- Don't need to use for each sex act
- Non-contraceptive



Next-Generation Microbicides

- Manufacturing options available for lead candidates
- Unit costs vary by formulation
- Possible issue with resistance (ARVs)



Microbicide Access Assumptions

- Staggered roll-out
 - Trial countries plus first adopters
- Pilot introductions
 - Understand operational issues
 - Understand use
- Integrate as part of HIV programme
 - But position separately?
 - SRH services?
- Need to generate demand



Microbicide Access Assumptions

- Address role of gate keepers
- First impressions count
 - Select for success
 - Set realistic expectations



Why Address Access Issues Now?

- With uncertainties why address access issues now?
 - Help manage currently high expectations
 - Develop conceptual framework
 - Pilot programme approach needed for early and next generation (designs may differ)
 - Identify information needs with longer lead times
 - Identify where can learn from other products
 - Help position microbicides in a dynamic field

HIV-Prevention Trial Results

